1. Matinas BioPharma Holdings, Inc. Receives NYSE American Delisting Notice
Matinas BioPharma Holdings, Inc. faces a critical compliance failure, receiving a formal notice from the NYSE American LLC that it is no longer in compliance with the exchange's continued listing standards. The 8-K filing, submitted on April 3, 2026, signals immediate and severe pressure on the company's public market ...